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Abstract
Background: The orexigenic effects of cannabinoids are limited by activation of the endocannabinoid degrading 
enzyme fatty acid amide hydrolase (FAAH). The aim of this study was to analyse whether FAAH alleles are associated 
with early and late onset obesity.
Methods: We initially assessed association of five single nucleotide polymorphisms (SNPs) in FAAH with early onset 
extreme obesity in up to 521 German obese children and both parents. SNPs with nominal p-values ≤ 0.1 were 
subsequently analysed in 235 independent German obesity families. SNPs associated with childhood obesity (p-values 
≤ 0.05) were further analysed in 8,491 adult individuals of a population-based cohort (KORA) for association with adult 
obesity. One SNP was further analysed in 985 German obese adults and 588 normal and underweight controls. In 
parallel, we screened the FAAH coding region for novel sequence variants in 92 extremely obese children using single-
stranded-conformation-polymorphism-analysis and denaturing HPLC and assessed the implication of the identified 
new variants for childhood obesity.
Results: The trio analysis revealed some evidence for an association of three SNPs in FAAH (rs324420 rs324419 and 
rs873978) with childhood obesity (two-sided p-values between 0.06 and 0.10). Although analyses of these variants in 
235 independent obesity families did not result in statistically significant effects (two-sided p-values between 0.14 and 
0.75), the combined analysis of all 603 obesity families supported the idea of an association of two SNPs in FAAH 
(rs324420 and rs2295632) with early onset extreme obesity (p-values between 0.02 and 0.03). No association was, 
however, found between these variants and adult obesity. The mutation screen revealed four novel variants, which 
were not associated with early onset obesity (p > 0.05).
Conclusions: As we observed some evidence for an association of the FAAH variants rs2295632 rs324420 with early 
onset but not adult obesity, we conclude that the FAAH variants analyzed here at least do not seem to play a major role 
in the etiology of obesity within our samples.
Background
An emerging body of evidence indicates that the endoge-
nous cannabinoid system is implicated in the regulation of
food intake and body weight maintenance. The endocan-
nabinoid system comprises the cannabinoid receptors
CNR1 and CNR 2 the endocannabinoids as their endoge-
nous ligands and the enzymes responsible for their biosyn-
thesis and degradation [1]. The most prominent
endocannabinoids are N-arachidonoylethanolamine (anand-
amide) [2] and 2-arachidonoylglycerol (2-AG) [3]. Both are
implicated in the regulation of food intake as exogenous
application of anandamide [4,5] and 2-AG [6] stimulate
food intake through activation of CNR1. Additionally,
hypothalamic levels of both, anandamide and 2-AG are
increased in response to fasting and decline upon refeeding
[6]. Furthermore, rodents with disturbed leptin signal trans-
duction (ob/ob, db/db mice as well as fa/fa rats) show ele-
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leptin treatment of ob/ob mice decreased hypothalamic lev-
els of both anandamide and 2-AG [7].
A characteristic feature of endocannabinoids is that they
are synthesized by cells on demand and undergo a rapid
degradation through specific hydrolases and lipases [1,8,9].
Among these the fatty acid amide hydrolase (FAAH) figure
prominently [10]. FAAH is a membrane-bound 60-65 kDa
protein that is widely distributed throughout the periphery
and the brain with specific central localization in the hypo-
thalamus, hippocampus, brain stem, cerebral cortex and
striatum [10,11]. Under alkaline conditions, FAAH rapidly
inhibits the orexigenic effects of anandamide by degrading
it to ethanolamine and arachidonic acid [1]. In accordance
to its pivotal role in degradation of anandamide, FAAH
mRNA expression is decreased by 59% in adipose tissue of
obese women, as compared to lean controls, whereas circu-
lating levels of anandamide and 2-AG were increased by
35% and 52% respectively [12]. Additionally, FAAH activ-
ity and expression is decreased in lymphocytes of obese
leptin deficient ob/ob mice [13] and leptin mediated STAT3
activation activates a CRE-like binding site on the FAAH
promoter [14]. Furthermore, association with obesity had
recently been reported for the A/A genotype of the FAAH
SNP rs324420 [15]. The SNP leads to the non-synonymous
exchange from proline to threonine at position 129 of the
FAAH protein (Pro129Thr). Functional in-vitro studies fur-
ther revealed that the 129Thr variant decreased the expres-
sion and activity of FAAH in humans, thus seemingly
corroborating the implication of the A-allele at rs324420 in
human obesity [16]. However, other studies could not sub-
stantiate the association of rs324420 with obesity [17-19].
As FAAH counteracts the orexigenic effects of endocan-
nabinoids through their rapid degradation, genetic variation
in FAAH that leads to decreased enzyme activity and thus
increased levels of endocannabinoids might be implicated
in the etiology of obesity. The aim of this study was there-




The ascertainment strategy was previously described in
detail [20]. The (extremely) obese children and adolescents
had age and gender specific BMI percentiles above 90th
(70% above 99th). Written informed consent was given by
all participants and in the case of minors, by their parents.
The study was approved by the Ethics Committees of the
Universities of Marburg and Duisburg-Essen and carried
out according to the Declaration of Helsinki.
The obesity trios comprised 521 (233 male) German
(extremely) obese children and adolescents (mean BMI of
31.86 ± 5.99 kg/m2, mean BMI percentile: 98.98 mean age
13.42 ± 3.09 years) and both biological parents. The parents
had a mean BMI of 30.02 ± 6.38 kg/m2 and a mean age of
42.32 ± 6.07 years.
The 235 independent obesity families included 501
(229 male) German (extremely) obese children and adoles-
cents (235 obese index patients and at least one obese sib-
ling) and both biological parents. The index patients had a
mean BMI of 32.28 ± 5.91 kg/m2 (mean BMI percentile
99.25 ± 1.48) and a mean age of 13.40 ± 2.63 years, the sib-
lings had a mean BMI of 28.57 ± 5.29 kg/m2 (mean BMI
percentile 97.37 ± 2.85) and a mean age of 15.15 ± 5.09
years. The parents had a mean BMI of 31.07 ± 6.03 kg/m2
and a mean age of 43.06 ± 5.81 years.
The epidemiological cohort comprised 8,491 (4,250
male) adult individuals of a German population-based study
group [KORA S3-S4]. The KORA sample is a representa-
tive study group of the population in the city and region of
Augsburg (Bavaria, Germany) [21]. The here reported
8,491 individuals had a mean age of 49.3 ± 27.12 years and
a mean BMI of 27.12 ± 4.59 kg/m2.
The case-control sample comprised 985 (360 male) Ger-
man obese adults (mean BMI: 36.04 ± 5.39 kg/m2; mean
age: 46.31 ± 14.74 years) and 588 healthy normal and
underweight controls (mean BMI: 19.34 ± 1.94 kg/m2;
mean age: 25.28 ± 4.42 years). All individuals were inde-
pendent from the KORA cohort und all cases had a BMI at
or above 30 kg/m2. The use of lean adults who were never
overweight or obese during childhood (assessed by inter-
view, [22]) as control group reduces the chances of misclas-
sification compared to the use of lean children as controls
who might become overweight in adulthood [22].
The FAAH coding region was screened in 92 German
extremely obese children and adolescents of the trio sam-
ples who contributed to the initially observed overtransmis-
sion of the rs2295632 G-allele (Table 1). The screened
individuals had a mean BMI of 33.61 ± 7.21 kg/m2 (mean
BMI percentile 99.2 ± 1.88) and a mean age of 14.13 ± 3.08
years. Association of the identified novel variants with




We initially assessed association of five SNPs in FAAH
(rs324420, rs324419, rs873978, rs2295632 and rs932816)
with early onset extreme obesity. SNP rs324420, rs324419,
rs873978 and rs2295632 were genotyped in 368 German
obesity trios using matrix-assisted laser desorption/ioniza-
tion time-of-flight mass spectrometry (MALDI-TOF MS,
Sequenom, San Diego, CA). The FAAH promoter SNP
rs932816 was genotyped in 521 German obesity trios using
restriction-fragment length polymorphism analyses (PCR-
RFLP). SNPs with nominal TDT p-values ≤ 0.1 were sub-
sequently analysed in additional 235 independent obesity
families. The 8,491 adult individuals of the population-
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mass spectrometry. Additionally, we genotyped the FAAH
SNP rs324420 in 985 independent German obese adults and
588 normal or underweight controls using PCR-RFLP.
Mutation screening
Single stranded conformation polymorphism analysis
(SSCP) and denaturing high pressure liquid chromatogra-
phy (dHPLC) were performed 92 extremely obese children
and adolescents which mainly contributed to the observed
overtransmission of the rs2295632 G-allele (Table 1). The
coding region of FAAH plus 79 nucleotides (nt) of the 5'-
untranslated region (UTR) and 154nt of 3'-UTR was ampli-
fied from genomic DNA using PCRs to yield 17 fragments.
The corresponding primer sequences, PCR conditions and
restriction enzymes can be obtained from the authors. SSCP
and dHPLC were performed as described previously [23].
All amplicons with SSCP or dHPLC patterns deviant from
wild type patterns were re-sequenced as described [22]. The
implication of the identified novel variants in FAAH for
childhood obesity was subsequently assessed in 521 Ger-
man obesity trios using PCR-RFLP or Taqman® genotyping
followed by TDT analyses [24].
TaqMan assay
the identified rare FAAH SNP rs41305628 was genotyped
using TaqMan® allelic discrimination assay (Applied Bio-
systems, Germany), call rates > 95%, with 100% concor-
dance of duplicates, using a Custom Assay. For validity of
the genotypes, alleles were rated independently by at least
two experienced individuals. Discrepancies were resolved
unambiguously either by reaching consensus or by retyp-
ing.
Statistics
Using Haploview 4.0 we estimated that the analyzed five
SNPs cover the common genetic variability of FAAH with a
mean max r2 of 0.48 (assuming a minor allele frequency
cut-off of 5% to define common variation using the Hap-
Map data for the European population), Tests for Hardy-







Transm. rate6 TDT 
p-value
GG 243 (0.478) G: 0.68
putative GA 209 (0.412)
rs932816 g.-272G/A promoter 508 AA 56 (0.110) A: 0.32 0.53 (A) 0.14
Exon 3, CC 248 (0.690) C: 0.83
CA 101 (0.282)
rs324420 c.385C/A Pro129Thr 359 AA 10 (0.028) A: 0.17 0.44 (A) 0.06
Exon 7 GG 258 (0.730) G: 0.85
GA 87 (0.247)
rs324419 c.895A/G Cys299Cys 353 AA 8 (0.023) A: 0.15 0.44 (A) 0.08
GG 351 (0.978) G: 0.99
GA 8 (0.022)
rs873978 IVS7-228G/A Intron 7 359 AA 0 (0.000) A: 0.01 0.88 (A) 0.10
GG 214 (0.610) G: 0.77
GT 113 (0.322)
rs2295632 *45G/T 3' region 351 TT 24 (0.068) T: 0.23 0.44 (T) 0.05
1 all SNPs were tested for Hardy-Weinberg equilibrium (p ≥ 0.05); 2 numbers are given according to Dunnen and Antonarakis 2001 Hum Genet 
109:121-124 [33]; 3 number of obesity trios; 4 genotype frequencies in the index patients of the obesity trios; 5 allele frequencies in the index 
patients of the obesity trios. These are very similar to the allele frequencies reported for the European population in the dbSNP database http:/
/www.ncbi.nlm.nih.gov/SNP/; 6 transmission rate of minor allele
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[25]. To identify the most promising SNPs for replication
studies, we first performed association analyses for five
SNPs in up to 521 obesity trios using the transmission-dis-
equilibrium tests (TDT) [24]. SNPs with nominal p values
≤ 0.1 were subsequently analysed in additional 235 inde-
pendent obesity families applying the pedigree disequilib-
rium test (PDT) [26]. We further considered both
independent datasets in a combined analysis comprising the
initial trios and the 235 obesity families using the PDT. For
each SNP we also assessed multiplicative genotype relative
risks (GRR) with a 95% confidence interval (95%-CI)
based on the ideas of Cordell and Clayton [27] using the
stata package 'gamenu' http://www-gene.cimr.cam.ac.uk/
clayton/software/stata/ which leads to some minor differ-
ences regarding p-values when compared to the PDT results
due to differences in estimation.
SNPs with nominal PDT p-values ≤ 0.05 in the combined
analyses were consecutively analysed in the population-
based KORA cohort regarding adult obesity. We stratified
the KORA probands into obese cases (BMI ≥ 30 kg/m2, N =
1,858) and normal or underweight controls (BMI < 25 kg/
m2, N = 2,818) and applied logistic regression using gender
and age as covariates and coding genotypes under a log-
additive genetic model. Assuming that the GRRs we esti-
mated from the combined family sample are also observ-
able in adults, we would have been able to confirm the
association of these three variants with an estimated power
between 80% and 97%. Sensitivity analyses assessing BMI
quantitatively by linear regression in all KORA probands,
generally supported our conclusions drawn below in the
results section. The strongest BMI effect per allele was 0.07
kg/m2 (p = 0.41) for SNP rs2295632. Note that a popula-
tion-based sample of 8,491 individuals would have a statis-
tical power ≥ 80% to detected much stronger BMI effects
(about 0.2 kg/m2) only (given all other assumptions being
similar to those in the nuclear families).
Association analysis for FAAH SNP rs324420 was also
performed in an additional independent 985 obese cases
and 588 lean and normal weight controls using the
Cochran-Armitage exact trend test. This case-control sam-
ple has a power of about 60% to confirm the GRR effect
observed in the initial combined family sample for
rs324420.
All reported p-values are two-sided, nominal and not cor-
rected for multiple testing. Power calculations were per-
formed using the program QUANTO http://hydra.usc.edu/
GxE applying a significance level of 5%, the observed mul-
tiplicative GRRs from the family sample (1.15-1.23) and
the corresponding frequencies of the risk alleles (70% -
81%) under a (log-) additive genetic model.
Results
No evidence for deviations from Hardy-Weinberg equilib-
rium was observed in all independent study groups (all
exact p > 0.05). Analyses of five SNPs in FAAH in up to
521 German obesity trios revealed some evidence for an
association of the G-allele at rs2295632 with early onset
extreme obesity (transmission rate of the G-allele 0.56;
nominal p = 0.045 Table 1). Moreover, we observed some
evidence for transmission disequilibrium for three other
FAAH SNPs (rs324420 rs324419 and rs873978) in the obe-
sity trios (nominal two-sided p-values between 0.06 and
0.10 Table 1). Analyses of these four variants in additional
235 independent obesity families could not substantiate this
observation (nominal two-sided p-values between 0.14 and
0.75 Table 2). However, as the small sample size of this
group might have contributed to the observed lack of asso-
ciation, we subsequently considered both independent data-
sets jointly. In the combined analyses of the 603 obesity
families we observed some evidence for an association of
two SNPs in FAAH (rs324420 and rs2295632 r2:0.69) with
childhood obesity (nominal two-sided p-values of 0.02 and
0.03 Table 2). Similarly, haplotype analysis for rs324420
and rs2295632 alleles supported this observation (omnibus
two-sided nominal p = 0.0387 Table 3). However, in the
population-based study we observed no evidence for an
association of the two variants with adult obesity (all p ≥
0.05; Table 4) or BMI (see Methods). Also analyses of
rs324420 in 985 German obese adults and 588 normal and
underweight controls revealed no association with adult
obesity (nominal two-sided p = 0.85).
In the mutation screen, we detected nine sequence vari-
ants, four of them are novel (Table 5). However, analyses of
the rare (minor allele frequency < 0.1) variants (IVS1+22G/
A, rs41305628 and IVS12-5C/T) in 521 German obesity
trios revealed no evidence for association of these variants
with early onset extreme obesity (all two-sided p ≥ 0.05).
Discussion
Analyses of five SNPs in FAAH in up to 521 German obe-
sity trios and 235 independent obesity families revealed
nominal evidence for association of two FAAH SNPs
(rs324420 and rs2295632) with early onset extreme obesity.
The FAAH SNP rs324420 A-allele has recently been
reported to be associated with drug and alcohol abuse [28]
and obesity [15]. Functional in-vitro studies further
revealed that expression and activity of FAAH is reduced in
isolated peripheral circulating T-lymphocytes of homozy-
gotes for the rs324420 A-allele, thus seemingly underlining
the observed association of rs324420 with obesity [16].
However, several other studies could not confirm the asso-
ciation of the rs324420 A-allele with obesity [17-19]. In
this study we also report lack of association of the rs324420
A-allele with obesity. Instead, we observed some evidence
for an association of the C-allele at rs324420 with child-
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taining to the association of rs324420 alleles with obesity, it
has to considered that associations of genetic variants with
complex phenotypes may vary with age [29] and ascertain-
ment scheme [30]. Accordingly, in the population-based
study, we observed no association of this variant with adult
obesity. Also analyses of rs324420 in 985 German obese
adults and 588 normal weight controls did not provide evi-
dence for an association. Due to discrepant results pertain-
ing to the implication of SNP rs324420 with obesity,
analyses of this variant in larger study groups are necessary
to clarify whether this variant is implicated in the etiology
of obesity. One of the limitations of our study is that the
here analyzed variants cover the common genetic variabil-
ity of FAAH with a mean max r2 of 0.48. Thus, it is possible
that other common variants which are not in LD with the
analyzed variants, might be of greater importance in the eti-
ology of childhood and/or adult obesity. However, although
rather small our mutation analysis in 93 obese children and
adolescents did not hint to a major impact of additional
mutations in FAAH in weight regulation. Moreover, FAAH
variants were not reported among the top-hits of recent
meta-analyses of genome-wide association studies for BMI
or obesity [31,32]; potentially also indicating their minor
importance for the etiology of obesity.
Conclusions
In summary we observed some evidence for an association
of two SNPs in FAAH (rs324420 and rs2295632) with early
onset but not adult obesity. This finding is in line with pre-
vious results showing lack of association of rs324420 with
adult obesity in a large population-based study [17]. As our
data were not corrected for multiple testing, we thus con-
clude that the FAAH variants analysed here may play a
Table 2: Genotypes and PDT results of the independent analysis of 235 obesity families and combined analyses of a total 
of 603 obesity families
SNP1 N3 Genotypes (fre-
quency %)4







rs324420 494 CC 320 (0.648) C: 0.802 0.47 (A) 0.14 0.02
(1.23, 1.03-1.48)
CA 152 (0.308)
AA 22 (0.044) A: 0.198
rs324419 491 GG 350 (0.713) G: 0.838 0.51 (A) 0.75 0.18
(0.94, 0.77-1.15)
GA 123 (0.251)
AA 18 (0.036) A: 0.162
rs873978 494 GG 485 (0.982) G: 0.991 0.49 (A) 0.56 0.08
(2.50, 0.97-6.44)
GA 9 (0.018)
AA 0 (0.000) A: 0.001
rs2295632 496 GG 266 (0.536) G: 0.732 0.483 (T) 0.32 0.03
(1.15, 0.98-1.35)
GT 194 (0.391)
TT 36 (0.073) T: 0.268
1 all SNPs were tested for Hardy-Weinberg equilibrium (p > 0.05); 2 numbers are given according to Dunnen and Antonarakis 2001 Hum Genet 
109:121-124 [33]; 3 number of obese children or adolescents of the 235 obesity families; 4 genotype frequencies in the index patients of the 
235 obesity families; 5 allele frequencies in the obese children or adolescents of the 235 obesity families. These are very similar to the allele 
frequencies reported for the European population in the dbSNP database http://www.ncbi.nlm.nih.gov/SNP/; 6 transmission rate of minor 
allele in 235 obesity families; 7 p-value of the combined analyses of the 603 obesity families.
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ples. To finally answer this question, further studies in
larger sample preferentially child and adolescents with an
extreme phenotype should be analysed.
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Table 4: Genotype frequencies and results of association analyses in the population-based KORA sample





OR1 95% CI p-value2
rs2295632 < 25 CC 1575 (0.560) C: 0.75 1.01 0.91 - 1.12 0.91
CA 1068 (0.379)
AA 172 (0.061) A: 0.25
≥ 30 CC 1051 (0.567) C: 0.75
CA 685 (0.369)
AA 119 (0.064) A: 0.25
rs324420 < 25 CC 1876 (0.666) C: 0.82 1.02 0.91 - 1.15 0.71
CA 855 (0.303)
AA 87 (0.031) A: 0.18
≥ 30 CC 1240 (0.668) C: 0.81
CA 547 (0.294)
AA 71 (0.038) A: 0.19
1 Odds ratios (OR) of the respective minor alleles were adjusted for sex and age; 2 Association tests were performed applying generalized linear 
model with the log-transformed binomial link function; p-values are two-sided and not corrected for multiple testing.
Table 3: Haplotype analysis of the FAAH SNPs rs324420 and rs2295632 in the 603 obesity families
rs324420 rs2295632 Frequency Transmitted Nontransmitted Transmissionrate1,2
A T 0.197 232 288 0.806
C T 0.064 99 94 1.053
A G 0.000 0 0 -
C G 0.739 340 289 1.176
1 Number of haplotypes were estimated by the EM-algorithm [34]; 2 omnibus p-value for association is p = 0.0387
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Table 5: FAAH: results of a mutation screen in 92 German extremely obese children and adolescents
Gene SNP Position1 Location 
Exchange
Genotypes n (%)2,4 Allele frequency
(%)3,4
FAAH IVS1+22G/A Intron 1 GG 31 (0.337) G: 0.60
GA 49 (0.533)
AA 12 (0.130) A: 0.40
FAAH rs324420 c.385C/A Exon 3 CC 82 (0.901) C: 0.95
CA 09 (0.099)
Pro129Thr AA 00 (0.000) A: 0.05
FAAH c.611C/T Exon 5 CC 90 (0.989) C: 0.99
CT 01 (0.011)
Thr204Ile TT 00 (0.000) T: 0.01
FAAH c.690C/G Exon 5 CC 90 (0.989) C: 0.99
CG 01 (0.011)
Ser230Ser GG 00 (0.000) G: 0.01
FAAH rs41305628 c.822G/A Exon 6 GG 88 (0.957) G: 0.98
GA 04 (0.043)
Glu274Glu AA 00 (0.000) A: 0.02
FAAH rs41309147 IVS6-41G/A Intron 6 GG 77 (0.837) G: 0.92
GA 15 (0.163)
AA 00 (0.000) A: 0.08
FAAH rs324419 c.895C/T Exon 7 CC 70 (0.761) C: 0.88
CT 22 (0.239)
Cys299Cys TT 00 (0.000) T: 0.12
FAAH IVS12-5C/T Intron 12 CC 79 (0.859) C: 0.93
CT 13 (0.141)
TT 00 (00.00) T: 0.07
FAAH rs2295632 IVS15+45G/T 3'UTR GG 18 (0.196) T: 0.60
GT 74 (0.804)
TT 00 (00.00) G: 0.40
1 numbers are given according to Dunnen and Antonarakis 2001 Hum Genet 109:121-124 [33];2 genotype frequencies in the 92 individuals 
used for the mutation screen; 3 allele frequencies in the 92 individuals used for the mutation screen. 4 As the mutation screen was performed 
in those individuals who contributed to the initially observed overtransmission of the FAAH SNP rs2295632 G-allele, this SNP is therefore not 
in Hardy-Weinberg-Equilibrium in these samples.
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